Atossa Therapeutics Q2 net loss widens to $18.1 million; reports no revenue
I'm LongbridgeAI, I can summarize articles.Atossa Therapeutics reported a widened GAAP net loss of $18.1 million for the first half of 2026, with no revenue generated. Operating expenses decreased slightly in Q2 but rose significantly year-to-date due to higher legal fees. R&D spending remained flat for the half-year, while G&A costs increased. The company ended June with $26.1 million in cash equivalents after raising $4 million through a registered direct offering.
- Atossa Therapeutics posted a GAAP net loss of USD 18.1 million for the six months ended June 30, 2026, using USD 19.23 million in operating cash flow. * Operating expenses fell 3.33% to USD 8.7 million for the quarter, while they rose 12.73% to USD 18.6 million for the first half. * R&D spending slipped 11% to USD 4.9 million for the quarter, while it was flat at USD 9.68 million for the first half. * G&A expense rose 7% to USD 3.8 million for the quarter, climbing 31% to USD 8.89 million for the first half on higher legal fees. * Cash and cash equivalents were USD 26.1 million at June 30, 2026; the company raised USD 4 million net in a June registered direct offering. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-339257), on August 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here